Trials / Completed
CompletedNCT00618046
Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Roxane Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- —
Summary
The objective of this study was to assess bioequivalence of a potential generic 600 mb oxcarbazepine tablet formulation compared with Novartis Pharmaceutical's 600 mg oxcarbazepine tablet, Trileptal, following a single 600 mg dose, administered with food.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxcarbazepine |
Timeline
- Start date
- 2004-11-01
- Primary completion
- 2004-11-01
- Completion
- 2004-11-01
- First posted
- 2008-02-18
- Last updated
- 2018-01-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00618046. Inclusion in this directory is not an endorsement.